225430 — KMPharmaceutical Co Income Statement
0.000.00%
Last trade - 00:00- KR₩16bn
- KR₩31bn
- KR₩14bn
Annual income statement for KMPharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 22,928 | 22,705 | 15,631 | 17,770 | 14,475 |
| Cost of Revenue | |||||
| Gross Profit | 5,941 | 5,663 | 3,225 | 4,910 | 3,606 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 22,216 | 22,341 | 17,686 | 18,869 | 17,044 |
| Operating Profit | 712 | 364 | -2,055 | -1,100 | -2,569 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 322 | -514 | -4,574 | -964 | -4,249 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 471 | -611 | -3,925 | -1,320 | -4,573 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 471 | -611 | -3,925 | -1,320 | -4,573 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 471 | -611 | -3,925 | -1,320 | -4,573 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 21.8 | -10.4 | -122 | -47.4 | -164 |
| Dividends per Share |